GnRH Agonist Pretreatment in Hysteroscopic Myomectomy

Azienda Ospedaliera S. Maria della Misericordia

Status: Completed

Conditions: Uterine Myoma

Treatments: Drug: Triptorelin 3.75 mg

Study type: Interventional

Funder types: Other

Identifiers

NCT01873378

GnRHa hysteroscopic myomectomy

Details and patient eligibility

About

The primary outcome of this study is to assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure. Moreover, we will investigate the intraoperative influence of such pharmacologic therapy in terms of distension liquid absorption and duration of the procedures.

Enrollment: 84 patients

Sex: Female

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• submucous myoma diagnosed by vaginal ultrasonography and confirmed by diagnostic hysteroscopy
• premenopausal status

Exclusion criteria

• present or past history of cancer
• pregnancy
• presence of associated multiple polyps
• presence of > 2 myomas
• associated nonhysteroscopic surgical procedures

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

84 participants in 2 patient groups

GnRH agonist pretreatment

Experimental group

Description:

triptorelin 3.75 mg, im, monthly, three times

Treatment:

Drug: Triptorelin 3.75 mg

No pharmacological treatment

No Intervention group